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Local transmission of dengue fever virus in Argentina
is increased by the presence of Aedes aegypti mosquitoes
and dengue outbreaks in neighboring countries. From 1995
to 2001, a laboratory-based active surveillance program
detected 922 dengue cases. Indigenous transmission
involving dengue-1 and -2 serotypes was confirmed only in
subtropical areas in northern Argentina.
T
he mosquito Aedes aegypti, which carries dengue
fever virus (DENV), reinfested Argentina in 1986 and
is well established in the subtropical and temperate areas
of the country (1); DENV infection was first diagnosed in
the laboratory in Argentina in 1997 (2). Early evidence of
sporadic DENV-2 circulation was detected in northwestern
Argentina in 1997 in a subtropical area; 19 of 404 indige-
nous cases were confirmed (2). Dengue surveillance in
Argentina was organized as a collaboration of the National
Department of Epidemiology, National Ministry of Health,
provincial departments of epidemiology, national and
provincial programs of vector control, and DENV labora-
tory network. (The DENV laboratory network is coordi-
nated by the Instituto Nacional de Enfermedades Virales
Humanas “Dr. Julio I. Maiztegui” [INEVH], the national
reference center of DENV diagnosis in Argentina, and the
Pan American Health Organization/World Health
Organization [PAHO/WHO] Collaborating Center in Viral
Hemorrhagic Fevers and Arboviruses.) This network was
established in the area at high risk for DENV in Argentina
based on the distribution of Aedes aegypti from the north
to 35°S, the latitude of Buenos Aires (1). Surveillance of
imported cases has also been performed in areas with no
Ae. aegypti infestation because of travelers from areas with
DENV transmission who reported DENV-like symptoms.
Laboratory-based surveillance has been closely coordinat-
ed between epidemiologic and clinical surveillance and
vector control measures. Goals of the laboratory network
include providing early information on timing and location
of transmission, disease severity, and serotypes and geno-
types present; predicting transmission; and guiding imple-
mentation of clinical and vector control measures. Actions
to alleviate DENV are tailored to each region, with the size
of the country, variable geographic characteristics, fund-
ing, and size of the population at risk taken into account.
These actions include vector control, health education,
community participation, adequate garbage handling, and
adequate water supply. Although the strategy is coordinat-
ed at a national level, many of the actions are decentralized
to the provincial and municipal levels. 
This system enabled us to detect an outbreak in the
same subtropical area in northwestern Argentina several
months after the first DENV introduction in 1997. Some
ongoing, undetected, transmissions may have occurred
because the same DENV serotype was circulating.
However, clinical surveillance did not detect cases com-
patible with DENV during those months, and laboratory
results were negative. We believe that this outbreak could
represent new activity because continuous transmission
was suspected (although not confirmed) in neighboring
countries. This area of Argentina has a continuous move-
ment of persons across the borders, and imported cases
were diagnosed before the outbreak. 
DENV-2 was isolated for the first time in the country
during an outbreak that affected only the Salta Province in
1998 (3). All cases identified then were classified as
dengue fever by using PAHO/WHO criteria (4). DENV
cases caused by DENV-2 had also been diagnosed in
Bolivia in 1996 and 1997 (5). In 1999 and 2000, an out-
break of at least 27,000 cases of DENV-1 occurred in
Paraguay. Evidence suggests that >100,000 cases of
DENV-1 may have occurred in the Asuncion District,
Paraguay (6). This outbreak spilled over into Argentina,
where several cases occurred in the northern part of the
country. We summarize the results of 6 years of surveil-
lance and, for the first time, document the circulation of
two DENV serotypes in Argentina.
The Study
We defined a notified case as any patient whose illness
was considered compatible with DENV by a health profes-
sional; samples from these cases were sent to provincial
laboratories or directly to the national reference laborato-
ry. Case definitions used for probable and confirmed cases
of dengue fever, dengue hemorrhagic fever, and dengue
shock syndrome were those proposed by PAHO (4).
Because DENV transmission was not endemic in
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ther introduction of the virus. Because the introduction of
DENV was relatively recent, the total population infected
relatively small, and no continuous transmission was
detected, all positive serologic samples obtained at the
provincial levels were sent to INEVH to be confirmed by
other techniques. If a bigger, confirmed outbreak occurs in
the future, we anticipate that a small number of positive
samples would be evaluated at INEVH. During interepi-
demic periods, we conducted laboratory surveillance of
febrile syndromes of undetermined etiology. Samples
obtained from other surveillance program for diseases that
are clinically similar to DENV (e.g., rubella, measles,
Argentine hemorrhagic fever, leptospirosis and other ill-
nesses fulfilling criteria for viral hemorrhagic fevers) were
also tested for DENV. 
Local-level physicians in Argentina were familiarized
with the case definitions for DENV syndromes from pub-
lished guidelines (4). After the discovery of the first occur-
rence of the virus and the organization of the national
DENV surveillance system, the training of local healthcare
personnel, including physicians and epidemiologists, was
intensified through periodic courses, meetings, and semi-
nars. In small localities, such as those in the north of the
country, only a few hospitals exist in each locality, and
most of them are government-owned; therefore, all person-
nel were informed and were willing to participate. In big-
ger provinces, such as Buenos Aires, the healthcare system
is organized into regions, each of which has several public
hospitals, but all of these hospitals are supported by a
provincial department of epidemiology. Periodic meetings
held to inform and train staff were quite efficient. We
found no evidence of any physicians unwilling to partici-
pate in the system.
The laboratory method used in Argentina has been
described in previous reports (2,3,7,8). Briefly, serum
samples taken from patients with suspected DENV infec-
tion 5 days after onset of symptoms (late acute) were test-
ed weekly during the summer and fall and monthly during
the rest of the year at provincial laboratories. The labora-
tories used a commercial kit (ultramicro enzyme-linked
immunosorbent assay capture immunoglobulin [Ig] M
dengue test, Instituto Pedro Kouri, Havana, Cuba) or IgM
antibody capture enzyme-linked immunosorbent assay
(MAC-ELISA). All positive samples and at least 10% of
negative samples were sent to INEVH for quality control
and confirmation. When the surveillance system was first
initiated, all negative samples were tested at the national
reference center. At INEVH, samples were tested by
MAC-ELISA, plaque reduction neutralization test
(PRNT), hemagglutination inhibition (HI) test, viral isola-
tion in C6/36 cells, and immunofluorescence detection
(using monoclonal antibodies obtained from PAHO), or
by polymerase chain reaction (PCR) techniques, accord-
ing to the date of onset. In addition, the capsid/premem-
brane and envelope/nonstructural protein 1 regions of
viral isolates were sequenced to determine the genotypes.
Acute-phase serum samples (<5 days after onset of symp-
toms) were sent directly to INEVH and assayed for viral
isolation or PCR; samples >5 days of onset were tested by
MAC-ELISA for IgM antibodies. During the convales-
cent-phase period, a second sample was obtained from
patients with positive results for DENV by MAC-ELISA
and from most patients with acute-phase samples (with
results either positive or negative by viral isolation or
PCR); these samples were tested along with the acute-
phase samples by using PRNT or HI tests. Serial dilutions
of each patient’s serum were tested against the four
DENV serotypes for 80% PRNT or HI tests. The DENV-
1 HAW, DENV-2 NGC, DENV-3 H87, and DENV-4
H241 strains were obtained from the Dengue Branch,
Centers for Disease Control and Prevention, San Juan,
Puerto Rico. Antigens from mice brains infected with
each DENV were prepared at INEVH by using the
sucrose-acetone method and used in MAC-ELISA and HI
tests. According to the IgG titers by PRNT or HI tests,
DENV cases were classified as primary or secondary.
Primary cases were indicated by titers <160 in the acute-
phase sample (<5 days after onset of symptoms), titers
<1,280 in the late acute- or convalescent-phase sample,
and low or null cross-reactivity among the different
DENV serotypes. Secondary cases were indicated by
titers >160 in the acute-phase sample, titers >2,560 in the
late acute- or convalescent-phase sample, and high cross-
reactivity among the different DENV serotypes. 
Alaboratory network including all provinces at risk for
DENV (according to Ae. aegypti distribution) was estab-
lished in 1998 (Figure 1). The national reference laborato-
ry, which is self-sufficient for production of key reagents
(such as antigens and antiserum), participates in the profi-
ciency tests organized under PAHO/WHO and maintains
country-proficiency tests on a continuing basis.
Commercial kits were evaluated at the national reference
center before being used in national programs.
Surveillance for yellow fever, St. Louis encephalitis, West
Nile virus, and other flaviviruses were also incorporated
into DENV diagnostic protocols. 
Thirty laboratories were designated by the National
Ministry of Health, the provincial ministries of health, and
the local municipalities to integrate the laboratory network
(Figure 1). Staff persons from 15 of those regional labora-
tories were trained on DENV diagnosis at INEVH, and 12
were actively working on DENV serologic surveillance.
Courses and rotations were part of the training ongoing
since the network of laboratories was organized. These 12
laboratories were evaluated on IgM detection by INEVH
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ratories had difficulties in obtaining reagents, keeping staff
because of lack of funding, and other operational prob-
lems, so they could not sustain the work through the entire
surveillance period. Training was emphasized, and INEVH
focused on the problems of these laboratories to maintain
high quality control. Staff from all 30 laboratories attend-
ed annual meetings at which the results and problems con-
cerning the organization of the laboratory, clinical, and
epidemiologic DENV surveillance were discussed.
Laboratories sent the samples directly to INEVH when
they were unable to carry out sample testing on their own. 
During the epidemiologic surveillance of cases compat-
ible with DENV from December 1995 to December 2001,
our laboratory received 493 serum samples from travelers
returning to Argentina with suspected DENV (Table 1) and
from case-patients with no epidemiologic data. Cases were
classified as imported or indigenous as a result of epidemi-
ologic analysis, considering travel histories in the 3 weeks
before onset of illness. Of 226 positive case-patients, 150
reported travel histories to Paraguay (127 cases), Brazil
(11 cases), Honduras (3 cases), Venezuela (3 cases),
Ecuador (1 case), Mexico (2 cases), Dominican Republic
(1 case), Puerto Rico (1 case), and the Virgin Islands (1
case). Seven other cases were “imported” to other
provinces inside the country during the DENV outbreaks
of 1998 and 2000. No epidemiologic data were available
for the remaining 69 cases. During the DENV outbreak in
Salta Province in 1998 (4), 21 persons reported that they
had traveled to Bolivia. We could not determine whether
infection occurred in Bolivia or Argentina, so these cases
were considered as probably imported but were included in
the total number of cases (378) for the outbreak (Table 2).
Imported cases were detected in different provinces
throughout the country in different years: Salta (1996,
2000), Buenos Aires (1997–2000), Santa Fe (1997, 1999,
2000), Misiones (1998, 2000), Jujuy (1998, 2000),
Cordoba (1998, 2000), Rio Negro (1998), Tucuman
(1999), Chaco (2000), Corrientes (2000), and Formosa
(2000); these cases involved either DENV-1, DENV-2, or
DENV-3 serotypes (Table 1).
From January 1997 to December 2001, a total of 2,987
serum samples were tested for suspected DENV from
provinces in the subtropical (north) and the temperate
(central) areas of the country; 696 samples were positive
(Table 2, Figure 2). Of these cases, 378 occurred during an
outbreak in Salta Province that occurred from January 3 to
May 31, 1998, and was caused by DENV-2 (3,7) (Table 2,
Figure 2). During the Salta outbreak, men and women
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Figure 1. Dengue laboratory network, Argentina. Star indicates the
Instituto “Dr. JI Malztegui” (INEVH), Pergamino, National
Reference Center ( )= number of local laboratories.





b  Viral isolates + amplicons
b  DENV serotype
c  Total
b by all techniques 
1995  0/18  ND  ND  ND  –  0/18 
1996  0/28  ND  ND  1/1  DENV-3  1/28 
1997  4/16  2/4  ND  ND  –  4/16 
1998  22/64  14/17  ND  ND  DENV-1,2  27/68 
1999  17/37  12/12  ND  0/2  DENV-1  23/45 
2000  142/307  9/10  43/44  19/31  DENV-1  162/279 
2001  9/9  3/3  2/2  ND  –  9/39 
Total  194/479  40/46  45/46  20/34  –  226/493
d 
aDENV, dengue fever virus; MAC-ELISA, immunoglobulin M antibody capture enzyme-linked immunosorbent assay; PRNT, plaque reduction neutralization test; HI, 
hemagglutination inhibition test; ND, not done. 
bPositive/tested.  
cIn most cases, the serotype was determined only by serologic testing unless we indicate otherwise that  virus isolation or polymerase chain reaction was also used. In 
many of these cases, the serotype could not be determined because of cross-reactions in serologic tests.  
dSome samples were tested by one technique, and others were tested by two or more techniques; therefore, these numbers do not represent the total obtained by adding 
the rows.  were equally affected. Prevalence in adults 15–79 years of
age (82.5%), was higher compared to that in children <14
years of age (17.5%). Because most samples came from
adults, the disease may have been subclinical or undetect-
ed in most children. The most affected locality in this
region was Tartagal (22°S, 63°W), which had an incidence
rate of 67.5 cases per 10,000 inhabitants. Serologic testing
by PRNT or HI for all four DENV serotypes in 154 cases
from this outbreak resulted in 38 (24.7%) that showed pri-
mary responses and 84 (54.5%) that showed secondary
responses. The secondary cases were considered to be
indigenous because none of these patients had traveled in
the previous 3 weeks. We did not gather any information
about traveling before those 3 weeks, so whether the
patients were infected by another flavivirus in Argentina or
in any other country before that is unknown. The remain-
ing 32 cases (20.7%) with borderline IgG titers could not
be classified. Previous exposure to other flaviviruses (e.g.,
St. Louis encephalitis or yellow fever likely due to vacci-
nation) explained 83% of the secondary serologic patterns;
the rest remained unexplained, suggesting the unrecog-
nized occurrence of previous infection with other DENV
serotypes or flaviviruses other than St. Louis encephalitis
or yellow fever (7). The second more important cluster of
DENV cases occurred during a DENV-1 outbreak in 2000
that affected Misiones, Formosa, and Jujuy Provinces
(Table 2, Figure 2), causing 294 cases from February 15 to
April 22. Most affected localities were Clorinda (Formosa
Province, 25°S, 57°W), with an incidence of 12.3 cases per
10,000 inhabitants and Iguazu (Misiones Province, 25°S,
54°W), with an incidence of 51.7 cases per 10,000 inhabi-
tants. 
DENV isolated in Argentina were also characterized
molecularly. DENV-2 isolated in Salta in 1997 and 1998
showed 98% to 99% nucleotide identity with DENV-2 iso-
lated from Brazil in 1990 and Jamaica in 1983 (Avilés et
al., unpub. data). DENV-1 isolated in 2000 from Misiones,
Formosa, and Jujuy Provinces showed 95% identity with a
DENV-1 strain isolated from French Guiana in 1989 and
91% identity with a DENV-1 strain isolated from the
Caribbean (Jamaica) in 1977 (8). 
Conclusions
Laboratory surveillance in Argentina enabled detection
of an early circulation of DENV in 1997 and confirmation
of two DENV outbreaks that occurred from 1998 to 2000.
This surveillance system identified 922 laboratory-diag-
nosed cases of DENV (696 indigenous, 157 imported, and
69 unknown) during the period of study. We obtained 38
DENV-1, 6 DENV-2, and 1 DENV-3 isolates or PCR
amplicons. Imported cases were detected in a wide sub-
tropical and temperate area of the country, while indige-
nous circulation of DENV occurred only in the subtropical
area of the country. The first outbreak caused by DENV-2
occurred in northwestern Argentina in 1998; the second
outbreak caused by DENV-1 occurred in the north-north-
eastern part of the country in 2000. Both outbreaks were
preceded by DENV outbreaks in neighboring countries.
The rates of DENV infections in neighboring countries
varied widely. A serosurvey conducted in Bolivia in 1997
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Table 2. Indigenous dengue virus cases in Argentina, 1997–2001 
Y  Province  MAC-ELISA
b  PRNT
b  HI
b  Viral isolates + amplicons
b  DENV serotype
 b  Total
b by all techniques 
1997  Salta  19/387  18/19  ND  1/36  DENV-2  19/404 
1998  Salta  359/589  139/143  79/80  5/112  DENV-2  378/701 
  Several  0/438  0/56  ND  ND  —  0/457 
1999  Salta  5/55  1/1  ND  0/15  —  5/55 
  Several  0/171  0/14  ND  0/4  —  0/173 
2000  Jujuy  2/63  ND  2/2  2/7  DENV-1  6/72 
  Formosa  37/89  1/31  8/21  7/57  DENV-1  50/195 
  Misiones  229/442  ND  25/27  9/25  DENV-1  238/469 
  Several  0/223  ND  0/19  0/20  —  0/249 
2001  Several  0/176  ND  0/2  0/46  —  0/212 
Total    651/2,633  159/264  114/151  24/322    696/2,987
c 
aDENV, dengue fever virus; MAC-ELISA, immunoglobulin M antibody capture enzyme-linked immunosorbent assay; PRNT, plaque reduction neutralization test; HI, 
hemagglutination inhibition test; ND, not done. 
bPositive/tested.  
cSome samples were tested by only one technique, others were tested by two or more techniques; thus, these numbers do not represent the total obtained by adding the 
rows.  
Figure 2. Geographic distribution of dengue cases in Argentina,
1997-2001. 
ain a neighborhood of Santa Cruz City (10,000 inhabitants)
showed that >5% of the populace was infected by DENV-
2 (5). Paraguay’s Ministry of Health reported an infection
rate of 49.3 cases per 10,000 inhabitants (including labora-
tory-diagnosed and reported cases) during a DENV-1 out-
break in 1999 and 2000 (6). Brazil reported incidence rates
in different municipalities in 2000 that varied from 0.037
to 866.9 cases per 10,000 inhabitants (9). The geographic
and climatologic situation in Argentina is favorable
because most of the country has a temperate climate.
Nevertheless, the introduction of different DENV
serotypes increases the risk for dengue hemorrhagic fever
because of the increased number of secondary DENV
infections. The sequence of serotypes in secondary infec-
tions seems to be an important risk factor for dengue hem-
orrhagic fever because DENV-2 secondary infections
account for most of those cases. Viral virulence related to
specific genotypes is also thought to play an important role
(10). All DENV cases that have occurred in Argentina to
date have been considered clinically to be dengue fever.
DENV-1 that circulated in Argentina during the period of
study belongs to an American genotype closely related to
viruses circulating previously in other American countries
that have been associated mostly with mild disease (8).
DENV-2 found in Argentina belongs to an Asian genotype
that has been associated with severe disease (11). In
Argentina, dengue hemorrhagic fever has not been report-
ed, possibly because the size of the affected population
was small and this complication occurs in a small propor-
tion of secondary DENV infections (18–125/1,000) (10),
and in an even smaller proportion of primary infections.
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